$1.39
6.20%
Nasdaq, Apr 21, 08:45 pm CET
ISIN
NL0015000AG6
Symbol
LVTX
Sector
Industry

LAVA Therapeutics NV Stock price

$1.31
+0.00 0.00% 1M
-0.34 20.61% 6M
+0.36 37.75% YTD
-1.63 55.44% 1Y
-2.70 67.33% 3Y
-13.69 91.27% 5Y
-13.69 91.27% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.08 6.50%
ISIN
NL0015000AG6
Symbol
LVTX
Sector
Industry

Key metrics

Market capitalization $34.46m
Enterprise Value $-36.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.91
EV/Sales (TTM) EV/Sales -3.08
P/S ratio (TTM) P/S ratio 2.88
P/B ratio (TTM) P/B ratio 1.24
Revenue growth (TTM) Revenue growth 77.01%
Revenue (TTM) Revenue $11.98m
EBIT (operating result TTM) EBIT $-29.52m
Free Cash Flow (TTM) Free Cash Flow $-19.30m
Cash position $76.58m
EPS (TTM) EPS $-0.93
P/E forward negative
Short interest 0.85%
Show more

Is LAVA Therapeutics NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

LAVA Therapeutics NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a LAVA Therapeutics NV forecast:

1x Buy
25%
3x Hold
75%

Analyst Opinions

4 Analysts have issued a LAVA Therapeutics NV forecast:

Buy
25%
Hold
75%

Financial data from LAVA Therapeutics NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
12 12
77% 77%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
8% 8%
95%
- Research and Development Expense 29 29
13% 13%
245%
-29 -29
-
-243%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -30 -30
32% 32%
-246%
Net Profit -25 -25
40% 40%
-209%

In millions USD.

Don't miss a Thing! We will send you all news about LAVA Therapeutics NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

LAVA Therapeutics NV Stock News

Neutral
GlobeNewsWire
5 days ago
Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform o...
Neutral
GlobeNewsWire
24 days ago
UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31...
Neutral
GlobeNewsWire
3 months ago
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-12...
More LAVA Therapeutics NV News

Company Profile

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Head office Netherlands
CEO Stephen Hurly
Employees 34
Founded 2016
Website www.lavatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today